Methods: In the first experiment, 8 retired-breeder female Sprague Dawley rats were given two injections of 20μg/kg zoledronate, 4 weeks apart. The control group (n=8) received normal saline. At the time of the second injection, the 1st mandibular molar was extracted. In the second experiment, 20 animals received 13 weekly injections of either 80μg/kg (n=10) zoledronate or saline (n=10). On the day of the final administration, the 1st mandibular molar was extracted followed by the 2nd mandibular molar a week later. In both experiments, the animals were sacrificed 8 weeks following extraction for gross and Micro-CT evaluation.
Results: With the smaller dose, 3 out of 8 (37.5%) rats in the zoledronate group had bone exposure versus none in the control group at 8 weeks. Decreased bone vitality was evident by microCT angiography. Preliminary results from the higher dose indicate that 100% of rats in the zoledronate group had bone exposure at 8 weeks, compared to 10% in the control group. Micro-CT showed sequestration of large bone segments from the alveolar process, but only in the high dose.
Conclusion: Osteonecrosis of the jaw can be modeled in rats receiving zoledronate treatment, with dental extraction being the only co-morbidity. Rate and severity of osteonecrosis increase with increasing dose and duration of zoledronate treatment, suggesting a causal relationship.